Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2025—This is the first of a new feature in CAP TODAY: a one-on-one virtual roundtable in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert. Tosoh Bioscience is the sponsor of the first such roundtable, and its sponsorship is in recognition of National Cancer Prevention Month, which was in February when the roundtable took place.
April 2025—If you read my monthly column often, you probably know that leadership among pathologists is one of my favorite topics. And one of the most important leadership roles we play as pathologists is as leaders of the laboratory diagnostic team. Our years of training prepare us to view a patient’s health holistically and to interpret test results in the context of the patient’s full clinical picture.
April 2025—Regulatory requirements in title 45, section 164.524 of the Code of Federal Regulations state that covered entities must provide patients or their designated representatives with patient health care records upon request. This is true for all laboratory testing, including such complex texting as next-generation sequencing (NGS). The protected health information that can be requested includes billing and payment records and clinic notes. Exceptions to the requirement to provide protected health information are very limited. However, questions arise with regard to complex laboratory testing, such as what information related to genomic testing should be included in the data set and what should be taken into consideration for the release and receipt of this information.
April 2025—Claudin-18.2 (CLDN18.2) is a biomarker for locally advanced or metastatic gastric and gastroesophageal junction adenocarcinomas that may respond to targeted therapy with monoclonal antibodies directed against CLDN18.2. Despite successful testing in clinical trials, no practical testing guidelines had been proposed at the time the authors’ article featured herein was published. Several preanalytical and analytical variables may interfere with CLDN18.2 staining interpretation. Therefore, the authors provided practical guidance on CLDN18.2 testing and scoring in gastric and gastroesophageal junction adenocarcinomas. They established criteria pertaining to sample characteristics, analytical requirements, staining evaluation, and reporting.
April 2025—Hirschsprung disease is characterized by the absence of ganglion cells in the intestinal wall. Determining whether ganglion cells are present in an effort to identify Hirschsprung disease is a cumbersome task for pathologists that may require frozen section analysis; histopathologic assessment of a rectal biopsy specimen (the gold standard); use of special stains, such as AChE; IHC analysis of calretinin or S100; or molecular and genetic testing. To assist pathologists with evaluating challenging frozen sections, the authors developed an artificial intelligence (AI) solution designed to enhance the detection of ganglion cells during intraoperative consultation. The AI model was trained using a mixed data set that combined 366 frozen section and 302 formalin-fixed, paraffin-embedded H&E-stained slides procured from 164 patients across three medical centers in Turkey. After scanning the slides, pathologists helped train the deep learning model by annotating ganglion cells present in the whole slide images (WSI).
April 2025—Chronic kidney disease is more common in people of African ancestry, with Americans of African descent having four times the risk compared with Americans of European descent. This disparity is largely due to the G1 and G2 genetic variants in the APOL1 gene, which increase the risk of developing chronic kidney disease (CKD) when inherited in a homozygous or compound heterozygous pattern. These variants, exclusive to African populations, likely evolved over 10,000 years ago due to their protective role against African sleeping sickness. The prevalence of these variants varies across sub-Saharan Africa, and data on their connection to CKD in African populations are limited.
April 2025
Q. Is it important to perform a manual differential on a CBC with a very low or very high mean corpuscular volume (MCV) result, or will a smear review/scan for RBC morphology suffice? Read answer.
Q. Do exact formalin fixation times and cold ischemia times have to be listed in the final pathology report for immunohistochemistry predictive marker testing so long as they are traceable on internal records (e.g. processor times, container label times)? Or is it sufficient to state that the formalin fixation and cold ischemia times meet ASCO/CAP recommendations of less than or equal to one hour cold ischemia time and greater than six hours but less than 72 hours formalin fixation time?
The only variable not in our final reports is our end of formalin time, but it is traceable through internal laboratory records. We document in the final report the time the tissue was removed from the body and the time it was placed in formalin. Then a blanket statement of “less than or equal to one hour cold ischemia time and greater than six but less than 72 hours formalin fixation time” is inserted in the comment when it applies. Read answer.
April 2025—UPMC Enterprises has introduced Ahavi, a real-world data platform on which clinical researchers, data scientists, and developers of artificial intelligence can validate AI solutions before the University of Pittsburgh Medical Center deploys them. The platform provides de-identified real-world health care data from more than 80 University of Pittsburgh Medical Center sources. Comprehensive structured and unstructured data have been sourced from approximately 5 million patients across 24 hospitals in order to train and refine AI models and develop predictive analytics and clinical decision-making tools.
April 2025—The U.S. District Court for the Eastern District of Texas ruled on March 31 in favor of the laboratory plaintiffs in the two consolidated cases challenging the validity of the Food and Drug Administration’s final rule on laboratory-developed tests. The plaintiffs in the cases were the American Clinical Laboratory Association, Association for Molecular Pathology, HealthTrackRX and HealthTrackRX Indiana, and pathologist Michael Laposata, MD. The ruling by Judge Sean D. Jordan ordered that the plaintiffs’ motions for summary judgment be granted. The final rule that would have regulated LDTs as medical devices under the Federal Food, Drug and Cosmetic Act was vacated.
